es-oh-MEP-ra-zole 
OTC:
Absorption: 90% absorbed following oral administration; food ↓ absorption.
Distribution: Unknown.
Protein Binding: 97%.
Metabolism/Excretion: Primarily metabolized by the liver via the CYP2C19 isoenzyme, with some metabolism by the CYP3A4 isoenzyme; (the CYP2C19 enzyme system exhibits genetic polymorphism; 15–20% of Asian patients and 3–5% of Caucasian and Black patients may be poor metabolizers and may have significantly ↑ esomeprazole concentrations and an ↑ risk of adverse effects); <1% excreted unchanged in urine.
Half-life: Children 1–11 yr: 0.42–0.88 hr; Adults: 1.0–1.5 hr.
Contraindicated in:
Use Cautiously in:
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, cutaneous lupus erythematosus, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.
F and E: hypocalcemia (especially if treatment duration ≥3 mo), hypokalemia (especially if treatment duration ≥3 mo), hypomagnesemia (especially if treatment duration ≥3 mo).
GI: abdominal pain, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), constipation, diarrhea, dry mouth, flatulence, fundic gland polyps, nausea.
GU: acute tubulointerstitial nephritis.
Hemat: vitamin B12 deficiency.
MS: bone fracture.
Neuro: headache.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, OR TUBULOINTERSTITIAL NEPHRITIS), systemic lupus erythematosus.
Drug-Drug:
Drug-Natural Products:
Gastroesophageal Reflux Disease
Hepatic Impairment
Reduction of Risk of Rebleeding of Gastric or Duodenal Ulcers After Therapeutic Endoscopy
Hepatic Impairment
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence (Triple Therapy)
Hepatic Impairment
Reduction in Risk of Gastric Ulcer During Continuous NSAID Therapy
Hepatic Impairment
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
Hepatic Impairment
(Generic available)
IV Administration:
NDC Code*
